Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. Pfizer has terminated the development of its oral obesity candidate danuglipron after a ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pfizer is scrapping another obesity pill, announcing Monday it will stop testing an experimental therapy ...

Company will instead invest in earlier-stage treatments for obesity Pfizer ... of a twice-daily version of danuglipron after high rates of nausea and vomiting led patients to drop out of a mid ...

The news will intensify pressure on Pfizer Chief Executive Officer Albert Bourla, who has repeatedly pointed to the drugmaker’s pipeline as an undervalued source of future growth. Pfizer ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company ... Pfizer previously discontinued a twice-daily version of the pill in December 2023 after patients ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing ... in late 2023 that it would abandon a twice-daily version of danuglipron that had ...

This is not Pfizer's first set back with danuglipron, specifically, either. The company discontinued a twice-daily ... Pfizer's pill. Pfizer scrapped a different once-daily obesity pill back ...